OBJECTIVES: HIV-infected people have elevated risk for lung cancer and higher mortality following cancer diagnosis than HIV-uninfected individuals. It is unclear whether HIV-infected individuals with lung cancer receive similar cancer treatment as HIV-uninfected individuals. DESIGN/ METHODS: We studied adults more than 18 years of age with lung cancer reported to the Texas Cancer Registry (N = 156 930) from 1995 to 2009. HIV status was determined by linkage with the Texas enhanced HIV/AIDS Reporting System. For nonsmall cell lung cancer (NSCLC) cases, we identified predictors of cancer treatment using logistic regression. We used Cox regression to evaluate effects of HIV and cancer treatment on mortality. RESULTS: Compared with HIV-uninfected lung cancer patients (N = 156 593), HIV-infected lung cancer patients (N = 337) were more frequently young, non-Hispanic black, men, and with distant stage disease. HIV-infected NSCLC patients less frequently received cancer treatment than HIV-uninfected patients [60.3 vs. 77.5%; odds ratio 0.39, 95% confidence interval (CI) 0.30-0.52, after adjustment for diagnosis year, age, sex, race, stage, and histologic subtype]. HIV infection was associated with higher lung cancer-specific mortality (hazard ratio 1.34, 95% CI 1.15-1.56, adjusted for demographics and tumor characteristics). Inclusion of cancer treatment in adjusted models slightly attenuated the effect of HIV on lung cancer-specific mortality (hazard ratio 1.25; 95% CI 1.06-1.47). Also, there was a suggestion that HIV was more strongly associated with mortality among untreated than among treated patients (adjusted hazard ratio 1.32 vs. 1.16, P-interaction = 0.34). CONCLUSION: HIV-infected NSCLC patients were less frequently treated for lung cancer than HIV-uninfected patients, which may have affected survival.
OBJECTIVES:HIV-infected people have elevated risk for lung cancer and higher mortality following cancer diagnosis than HIV-uninfected individuals. It is unclear whether HIV-infected individuals with lung cancer receive similar cancer treatment as HIV-uninfected individuals. DESIGN/ METHODS: We studied adults more than 18 years of age with lung cancer reported to the Texas Cancer Registry (N = 156 930) from 1995 to 2009. HIV status was determined by linkage with the Texas enhanced HIV/AIDS Reporting System. For nonsmall cell lung cancer (NSCLC) cases, we identified predictors of cancer treatment using logistic regression. We used Cox regression to evaluate effects of HIV and cancer treatment on mortality. RESULTS: Compared with HIV-uninfected lung cancerpatients (N = 156 593), HIV-infected lung cancerpatients (N = 337) were more frequently young, non-Hispanic black, men, and with distant stage disease. HIV-infected NSCLCpatients less frequently received cancer treatment than HIV-uninfectedpatients [60.3 vs. 77.5%; odds ratio 0.39, 95% confidence interval (CI) 0.30-0.52, after adjustment for diagnosis year, age, sex, race, stage, and histologic subtype]. HIV infection was associated with higher lung cancer-specific mortality (hazard ratio 1.34, 95% CI 1.15-1.56, adjusted for demographics and tumor characteristics). Inclusion of cancer treatment in adjusted models slightly attenuated the effect of HIV on lung cancer-specific mortality (hazard ratio 1.25; 95% CI 1.06-1.47). Also, there was a suggestion that HIV was more strongly associated with mortality among untreated than among treated patients (adjusted hazard ratio 1.32 vs. 1.16, P-interaction = 0.34). CONCLUSION:HIV-infected NSCLCpatients were less frequently treated for lung cancer than HIV-uninfectedpatients, which may have affected survival.
Authors: Malcolm V Brock; Craig M Hooker; Eric A Engels; Richard D Moore; Maura L Gillison; Anthony J Alberg; Jeanne C Keruly; Stephen C Yang; Richard F Heitmiller; Stephen B Baylin; James G Herman; Julie R Brahmer Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Anil K Chaturvedi; Ruth M Pfeiffer; Leonard Chang; James J Goedert; Robert J Biggar; Eric A Engels Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: Gita Suneja; Matthew Boyer; Baligh R Yehia; Meredith S Shiels; Eric A Engels; Justin E Bekelman; Judith A Long Journal: J Oncol Pract Date: 2015-04-14 Impact factor: 3.840
Authors: Anna E Coghill; Ruth M Pfeiffer; Meredith S Shiels; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-15 Impact factor: 4.254
Authors: Sandra Medina-Moreno; Juan C Zapata; Mackenzie L Cottrell; Nhut M Le; Sijia Tao; Joseph Bryant; Edward Sausville; Raymond F Schinazi; Angela Dm Kashuba; Robert R Redfield; Alonso Heredia Journal: Antivir Ther Date: 2019
Authors: Adam B Murphy; Ramona Bhatia; Iman K Martin; David A Klein; Courtney M P Hollowell; Yaw Nyame; Elodi Dielubanza; Chad Achenbach; Rick A Kittles Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-25 Impact factor: 4.254
Authors: Scott Dryden-Peterson; Memory Bvochora-Nsingo; Gita Suneja; Jason A Efstathiou; Surbhi Grover; Sebathu Chiyapo; Doreen Ramogola-Masire; Malebogo Kebabonye-Pusoentsi; Rebecca Clayman; Abigail C Mapes; Neo Tapela; Aida Asmelash; Heluf Medhin; Akila N Viswanathan; Anthony H Russell; Lilie L Lin; Mukendi K A Kayembe; Mompati Mmalane; Thomas C Randall; Bruce Chabner; Shahin Lockman Journal: J Clin Oncol Date: 2016-11-01 Impact factor: 44.544